Prognostic Scoring Systems in Allogeneic Hematopoietic Stem Cell Transplantation: Where Do We Stand?

Rashmika Potdar, Gabor Varadi, Joshua Fein, Myriam Labopin, Arnon Nagler, Roni Shouval

Research output: Contribution to journalReview articlepeer-review

28 Scopus citations


Allogeneic hematopoietic stem cell transplantation is a potentially curative treatment for many hematologic disorders. Maximizing the benefit of transplantation for disease control while minimizing the risk for associated complications remains the field's leading challenge. This challenge has prompted the development of multiple prognostic scoring systems over the last 2 decades. Prognostic scores can be used for informed decision making, better patient counseling, design of interventional trials, and analysis of prospective and retrospective data. They are also helpful in treatment allocation and personalization according to predicted risk. A better understanding of the molecular and cytogenetic features of the disease, along with the advent of novel therapies, has increased the need for reliable prognostication of which patients will benefit most from transplantation. Here we review the clinical role of the prognostic systems currently in clinical use, examining both their strengths and their limitations.

Original languageEnglish
Pages (from-to)1839-1846
Number of pages8
JournalBiology of Blood and Marrow Transplantation
Issue number11
StatePublished - Nov 2017
Externally publishedYes

Bibliographical note

Publisher Copyright:
© 2017 The American Society for Blood and Marrow Transplantation


  • Allogeneic hematopoietic stem cell transplantation
  • Nonrelapse mortality
  • Prognosis
  • Risk score


Dive into the research topics of 'Prognostic Scoring Systems in Allogeneic Hematopoietic Stem Cell Transplantation: Where Do We Stand?'. Together they form a unique fingerprint.

Cite this